Scaffold Vaccines for Generating Robust and Tunable Antibody Responses

Traditional bolus vaccines often fail to sustain robust adaptive immune responses, typically requiring multiple booster shots for optimal efficacy. Additionally, these provide few opportunities control the resulting subclasses of antibodies produced, which can mediate effector functions relevant distinct disease settings. Here, it is found that three scaffold-based vaccines, fabricated from poly(lactide-co-glycolide) (PLG), mesoporous silica rods, and alginate cryogels, induce robust, long-term antibody responses a model peptide antigen gonadotropin-releasing hormone with single-shot immunization. Compared vaccine, PLG prolong germinal center formation T follicular helper cell responses. Altering presentation release adjuvant (cytosine-guanosine oligodeoxynucleotide, CpG) tunes IgG subclasses. Further, elicit strong humoral against disease-associated antigens HER2 pathogenic E. coli, protecting mice coli challenge more effectively than vaccine. Scaffold-based may thus enable potent, durable versatile disease.